4//SEC Filing
FLEMING STANDISH 4
Accession 0001181431-13-029557
CIK 0001131543other
Filed
May 20, 8:00 PM ET
Accepted
May 21, 7:41 PM ET
Size
27.4 KB
Accession
0001181431-13-029557
Insider Transaction Report
Form 4
FLEMING STANDISH
Director
Transactions
- Conversion
Series D Preferred Stock
2013-05-21−1,112,781→ 0 total(indirect: See Footnote)→ Common Stock (102,450 underlying) - Conversion
Common Stock
2013-05-21+53,579→ 77,798 total(indirect: See Footnote) - Conversion
Common Stock
2013-05-21+102,450→ 180,248 total(indirect: See Footnote) - Conversion
Series E Preferred Stock
2013-05-21−5,371,063→ 0 total(indirect: See Footnote)→ Common Stock (223,795 underlying) - Conversion
Series C Preferred Stock
2013-05-21−1,285,918→ 0 total(indirect: See Footnote)→ Common Stock (53,579 underlying) - Conversion
Series D-2 Preferred Stock
2013-05-21−7,171,250→ 0 total(indirect: See Footnote)→ Common Stock (298,802 underlying) - Conversion
Series B Preferred Stock
2013-05-21−578,033→ 0 total(indirect: See Footnote)→ Common Stock (24,084 underlying) - Conversion
Common Stock
2013-05-21+24,084→ 24,219 total(indirect: See Footnote) - Award
Stock Option (right to buy)
2013-05-21−7,085→ 7,085 totalExercise: $6.66Exp: 2023-05-20→ Common Stock (7,085 underlying) - Conversion
Common Stock
2013-05-21+298,802→ 479,050 total(indirect: See Footnote) - Conversion
Common Stock
2013-05-21+223,795→ 702,845 total(indirect: See Footnote) - Purchase
Common Stock
2013-05-21$8.00/sh+263,301$2,106,408→ 966,146 total(indirect: See Footnote)
Footnotes (8)
- [F1]Upon the closing of the Issuer's initial public offering, every 24 shares of Series B Preferred Stock automatically converted into 1 share of Common Stock for no additional consideration and had no expiration date.
- [F2]The securities are held by Forward Ventures IV, L.P., or Forward IV, Forward Ventures IV B, L.P., or Forward IV B and Forward Ventures IV-C, L.P., or Forward IV-C. The Reporting Person, one of the Issuer's directors, and Dr. Ivor Royston, the managing members of Forward IV Associates, LLC the general partner of Forward IV, Forward IV B and Forward IV-C, and Dr. Stuart Collinson, the key member of Forward IV Associates, LLC, share voting and investment control over the securities held by Forward IV, Forward IV B and Forward IV-C, but disclaim beneficial ownership, except to the extent of their pecuniary interests therein.
- [F3]Upon the closing of the Issuer's initial public offering, every 24 shares of Series C Preferred Stock automatically converted into 1 share of Common Stock for no additional consideration and had no expiration date.
- [F4]Upon the closing of the Issuer's initial public offering, every 10.86166 shares of Series D Preferred Stock automatically converted into 1 share of Common Stock for no additional consideration and had no expiration date. The conversion ratio was incorrectly stated in the Reporting Person's Form 3.
- [F5]Upon the closing of the Issuer's initial public offering, every 24 shares of Series D-2 Preferred Stock automatically converted into 1 share of Common Stock for no additional consideration and had no expiration date.
- [F6]Upon the closing of the Issuer's initial public offering, every 24 shares of Series E Preferred Stock automatically converted into 1 share of Common Stock for no additional consideration and had no expiration date.
- [F7]One-third of the shares will vest on the first, second and third year anniversaries of the date of grant, such that the stock option is fully vested on May 21, 2016, subject to the optionee's continuous service with the Issuer through such vesting date.
- [F8]The shares were purchased in a private placement concurrent with the closing of the Issuers' initial public offering.
Documents
Issuer
AMBIT BIOSCIENCES CORP
CIK 0001131543
Entity typeother
Related Parties
1- filerCIK 0001026764
Filing Metadata
- Form type
- 4
- Filed
- May 20, 8:00 PM ET
- Accepted
- May 21, 7:41 PM ET
- Size
- 27.4 KB